PubRank

Anthony M Joshua

Author PubWeight™ 49.01‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013 18.08
2 Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014 11.05
3 Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006 3.08
4 Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008 2.66
5 Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 2006 2.23
6 PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res 2011 1.46
7 TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res 2013 1.45
8 Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer 2006 1.29
9 PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol 2012 1.26
10 Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J Clin Oncol 2009 1.25
11 Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J 2013 1.00
12 Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs). PLoS One 2010 0.95
13 Prostate cancer as a model system for genetic diversity in tumors. Adv Cancer Res 2011 0.91
14 Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs 2010 0.88
15 Renal cell carcinoma bone metastases: clinical advances. Ther Adv Med Oncol 2010 0.87
16 Advances in the adjuvant treatment of colorectal cancer. ANZ J Surg 2006 0.83
17 The changing landscape in metastatic castration-resistant prostate cancer. Curr Opin Support Palliat Care 2013 0.79
18 Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers. BJU Int 2012 0.79
19 A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate 2014 0.79
20 18F-FDG-PET/CT in the Staging and Management of Melanoma: A Prospective Multicenter Ontario PET Registry Study. Clin Nucl Med 2016 0.78
21 Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone. Prostate 2014 0.75
22 Use of a clinical assistant to screen patients with genitourinary cancer to encourage entry into clinical trials and use of supportive medication: a pilot project at a Canadian cancer center. Clin Genitourin Cancer 2013 0.75